Related Experiment Video
Updated: Aug 9, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
Inhaled tobramycin in children with acute bacterial rhinopharyngitis
A Varricchio1, D Tricarico, A De Lucia
1Dipartimento Universitario di Patologia della Testa e del Collo, del Cavo Orale e della Comunicazione Audio-Verbale, Seconda Università degli Studi di Napoli, Naples, Italy.
Insights
Inhaled tobramycin effectively treated acute bacterial rhinopharyngitis in children, showing superior results compared to oral amoxicillin/clavulanate. This topical antibiotic offers a safe and simple alternative for pediatric respiratory infections.
Area of Science:
- Pediatric Otolaryngology
- Infectious Diseases
- Respiratory Medicine
Background:
- Antibiotic overuse for rhinopharyngitis contributes to antibiotic resistance.
- Topical antibiotic administration may mitigate resistance development.
- Acute bacterial rhinopharyngitis requires effective and safe treatment options for children.
Purpose of the Study:
- To evaluate the efficacy and safety of inhaled tobramycin for acute bacterial rhinopharyngitis in children.
- To compare inhaled tobramycin with oral amoxicillin/clavulanate in pediatric patients.
- To assess the impact on clinical symptoms and objective measures of nasal and middle ear inflammation.
Main Methods:
- A randomized, parallel-group, double-blind trial involving children aged 3-6 years with acute bacterial rhinopharyngitis.
- Treatment groups received either inhaled tobramycin (15 mg) or oral amoxicillin/clavulanate (50 mg/Kg) twice daily for 10 days.
- Outcome measures included nasal obstruction, mucopurulent rhinorrhea, post-nasal drip, adenoidal hypertrophy, tympanic inflammation, tympanometry, rhinomanometry, and microbial cultures.
Main Results:
- Both treatments significantly improved all assessed parameters (p<0.01).
- Inhaled tobramycin demonstrated superior improvement in nasal obstruction (p<0.05), adenoidal hypertrophy (p<0.01), tympanic inflammation (p<0.01), rhinomanometry (p<0.01), and culture outcomes (p<0.05) compared to oral amoxicillin/clavulanate.
- 311 children completed the study, with 156 in the tobramycin group and 155 in the amoxicillin/clavulanate group.
Conclusions:
- Inhaled tobramycin is a safe, effective, and user-friendly treatment for acute bacterial rhinopharyngitis in children.
- This therapeutic approach may help reduce the incidence of antibiotic resistance.
- Inhaled tobramycin presents a promising alternative to systemic antibiotics for pediatric respiratory tract infections.
Abstract:
Antibiotic abuse for treating rhinopharyngitis induces the occurrence of resistant bacteria. As topical drugs might reduce this phenomenon, the aims of our study were to evaluate inhaled tobramycin in children with acute bacterial rhinopharyngitis and to compare it with oral amoxicillin/clavulanate. The trial was conducted as randomized, parallel group and double blind. Children, aged 3-6 years, with acute bacterial rhinopharyngitis were treated with 15 mg of aerosolized tobramycin (Group A) or 50 mg/Kg of amoxicillin/clavulanate (Group B) twice daily for 10 days. The following parameters were assessed: nasal obstruction, mucopurulent rhinorrhea, post-nasal drip, adenoidal hypertrophy, tympanic inflammation, tympanogram, rhinomanometry and cultures. Of 416 patients screened, 311 children (178 females and 133 males), median age 4.5 years, completed the study: 156 in Group A and 155 in Group B. Both treatments improved all parameters (p<0.01 for all). Intergroup analysis showed that inhaled tobramycin induced a better improvement versus amoxicillin/clavulanate concerning nasal obstruction (p<0.05), adenoidal hypertrophy (p<0.01), tympanic inflammation (p<0.01), rhinomanometry (p<0.01) and cultures (p<0.05). In conclusion, inhaled tobramycin may represent a valid treatment for acute bacterial rhinopharyngitis in children, as it is effective, safe, economic and simple to use.
Related Concept Videos
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Microbiota of the Respiratory Tract
Inhaled Medications
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Chronic Pharyngitis
Etiology
It often arises from persistent viral or bacterial infections affecting sinuses and tonsils.
Additional contributing factors include inadequate dental hygiene, mouth breathing, recurring tonsillitis, allergic rhinitis, laryngopharyngeal reflux, and exposure to smoke, chemicals, and other environmental pollutants. Allergic reactions to pollen, mold, and pet dander, chronic cough, excessive voice usage,...